Barclays initiates Exelixis stock coverage with Equalweight rating

Barclays initiated coverage on Exelixis with an Equalweight rating and a $40 price target, projecting cabozantinib's mid-single-digit growth until its 2029 patent expiry but forecasting total revenue below consensus due to pipeline product expectations and noting competitive challenges for zanzalintinib. This follows Exelixis's Q2 Cabometyx sales of $520 million missing Wall Street expectations of $530 million, prompting several analyst price target adjustments downwards, although Goldman Sachs initiated with a Buy rating and a $47 price target, citing zanzalintinib's potential to offset future revenue losses. The company faces a complex outlook with core asset patent expiry, mixed pipeline prospects, and divergent analyst sentiment regarding its future growth drivers.

Analysis

Exelixis (EXEL) presents a complex investment case, characterized by divergent analyst sentiment and a critical juncture between its current cash cow and future growth prospects. Barclays initiated coverage with a neutral 'Equalweight' rating and a $40 price target, forecasting that the primary drug, cabozantinib, will see mid-single-digit growth until its patent expires in 2029. Crucially, Barclays' 2029 total revenue forecast is 8% below consensus, reflecting skepticism about the sales contribution from pipeline products like zanzalintinib, which they believe faces a challenging competitive landscape. This contrasts sharply with Goldman Sachs' 'Buy' rating and $47 price target, which is predicated on zanzalintinib's potential to offset future revenue declines. The cautious sentiment is further supported by recent events, including a Q2 sales miss for Cabometyx ($520M reported vs. $530M expected) and Exelixis's decision to halt the Phase 3 STELLAR-305 trial for zanzalintinib. These developments prompted price target reductions from RBC Capital, Truist Securities, and H.C. Wainwright. Despite these headwinds, the company's fundamentals remain strong, with a 96.59% gross margin and 10.73% revenue growth over the last twelve months, leading to an 'undervalued' assessment from InvestingPro. Recent leadership changes in R&D underscore the company's ongoing strategic adjustments in this pivotal period.

Key Decisions for Investors

• Investors should weigh the divergent analyst outlooks, particularly the contrast between Goldman's bullish view on the pipeline and Barclays' more cautious stance, as the valuation hinges on zanzalintinib's ability to offset the 2029 cabozantinib patent cliff.
• Closely monitor all clinical trial data and regulatory updates for the pipeline, as the recent halt of the STELLAR-305 trial elevates the risk profile and makes future zanzalintinib developments the primary catalyst for the stock.
• Pay attention to near-term revenue performance of Cabometyx relative to consensus, as the recent Q2 sales miss could signal emerging headwinds for the company's core revenue stream.
• Given the disconnect between strong historical fundamentals and future uncertainty, consider that the stock will likely be highly sensitive to news flow, presenting tactical opportunities around clinical data releases and earnings reports.